Drug Profile
GTS 21
Alternative Names: DMXB-A; DMXB-A sustained release; DMXB-A-SRLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical; University of Florida
- Developer CoMentis
- Class Benzylidene compounds; Neuroprotectants; Nootropics; Pyridines; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
- Discontinued Alzheimer's disease; Cognition disorders
Most Recent Events
- 28 Apr 2015 University of Florida plans a phase II trial for Smoking withdrawal in USA (NCT02432066)
- 04 Apr 2014 University of Colorado at Denver plans a phase I trial for Autistic disorder in USA (NCT02111551)
- 07 Apr 2008 GTS 21 is still in Phase-I/II trials for Attention deficit hyperactivity disorder in USA